Tag: Cancer: Leukemia
Improvements Seen in Post-Allo-HCT Outcomes for Seniors With Leukemia
Reduction in relapse incidence observed over time, as well as improvement in leukemia-free survival, overall survival
FDA Approves First CAR T-Cell Therapy for Adults With Leukemia or Lymphoma
20 percent of patients treated with Breyanzi achieved a complete response
Worse Overall Survival Seen for Adults With Leukemia With CNS Involvement
Overall survival inferior for acute myeloid leukemia patients with versus without central nervous system involvement
Outcomes Similar for Therapy-Related, De Novo MDS After Haplo-HSCT
Three-year overall and disease-free survival, three-year cumulative incidence of relapse similar between the groups
Risk for Cancer Increased for Relatives of Patients With Leukemia
Study finds increased risk for cancer overall and for specific cancers for first- and second-degree relatives
Allogeneic HCT After Primary Induction Failure Beneficial in Leukemia
Overall survival rates were 29.8 and 21.6 percent five and 10 years after hematopoietic stem cell transplant
Peripheral Blood Haplo-SCT Feasible for Leukemia Patients 70 Years and Older
Haploidentical stem cell transplantation using nonmyeloablative conditioning regimen effective in highly selected patients
Air Pollution May Increase Risk for Childhood Leukemia
Strongest association seen for benzene exposure and acute myeloid leukemia
ASH: MRD-Directed Ibrutinib-Venetoclax Treatment Beneficial in Leukemia
Improvement in survival seen with measurable residual disease-directed ibrutinib-venetoclax versus fludarabine-cyclophosphamide-rituximab
Poor Physical Function Persists in Childhood Cancer Survivors
Findings seen for patients diagnosed with acute lymphoblastic leukemia and non-Hodgkin lymphoma from the 1970s through the 1990s
